USFDA Grants Tentative Approval to Zydus Lifesciences for Generic Crohn’s Disease Drug (Budesonide 4mg)

Zydus Lifesciences Limited (Zydus) has achieved a significant regulatory milestone, securing tentative approval from the United States Food and Drug Administration (USFDA) for its Budesonide delayed-release capsules, 4 mg.

This formulation is intended as a generic version of the Reference Listed Drug (USRLD), which is identified as Tarpeyo Capsules, 4 mg.

Key Details of the Approval

Product: Budesonide delayed-release capsules, 4 mg.
Approval Status: Tentative Approval. This status indicates that the drug has met all the necessary quality, efficacy, and manufacturing standards set by the FDA. However, the final, full approval and subsequent commercial launch are currently deferred due to existing patents or market exclusivities held by the innovator company for the reference product.
Therapeutic Indication: The Zydus capsule is approved for the treatment of mild to moderate active Crohn’s disease that specifically involves the ileum (the final section of the small intestine) and/or the ascending colon (the beginning of the large intestine).
Patient Population: The drug is indicated for use in adults and pediatric patients 8 years of age and older.
Manufacturing Site: The production of the Budesonide delayed-release capsules will be handled at Zydus Pharmaceuticals Ltd.’s dedicated manufacturing unit, SEZ-II.

Context on the Drug and Zydus’s Portfolio

Budesonide is a locally-acting corticosteroid with high topical anti-inflammatory activity and low systemic exposure, meaning it primarily works directly in the gut with fewer systemic steroid side effects.

This tentative approval further bolsters Zydus’s Abbreviated New Drug Application (ANDA) portfolio. As of a recent update, the Zydus group holds a substantial portfolio of 425 approvals from the USFDA, having filed 487 ANDAs since the commencement of its filing process in the financial year 2003-04.

The company is now positioned to launch this product in the U.S. market immediately upon the expiration or successful legal resolution of the intellectual property rights pertaining to the reference product.